Form 6-K NeuroSense Therapeutics For: Oct 26

Mon, 26 Oct 2026 12:45:00 -0400

si-local-file:///var/storage/secattach/20261026/27232971.html

Form 6-K NeuroSense Therapeutics For: Oct 19

Mon, 19 Oct 2026 09:48:00 -0400

si-local-file:///var/storage/secattach/20261019/27202000.html

NeuroSense files U.S. patent for PrimeC in traumatic brain injury

Mon, 19 Oct 2026 08:28:08 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has filed a patent application with the U.S. Patent and Trademark Office covering methods of treating traumatic brain injury (TBI) using ciprofloxacin and celecoxib, the active ingredients in its drug candidate PrimeC.

The application covers a range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as long-term consequences such as chronic traumatic encephalopathy (CTE). If granted, the patent is expected to provide protection through 2047, subject to any extensions.

ALS remains NeuroSense's primary development focus. The company stated it is evaluating TBI-focused research initiatives through strategic collaborations,

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

Mon, 19 Oct 2026 08:25:00 -0400

Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE)
Positions PrimeC for potential expansion beyond ALS into an indication affecting millions worldwide, with no approved disease-modifying therapy

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

Mon, 19 Oct 2026 08:25:00 -0400

Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic encephalopathy (CTE)
Positions PrimeC for potential expansion beyond ALS into an indication affecting millions worldwide, with no approved disease-modifying therapy

Form 6-K NeuroSense Therapeutics For: Oct 13

Tue, 13 Oct 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20261013/27177959.html

NeuroSense schedules Nasdaq hearing for November amid listing issues

Tue, 13 Oct 2026 08:31:01 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that its hearing before the Nasdaq Hearings Panel is scheduled for November 10, 2026, following its appeal of a Staff Delisting Determination issued October 1, 2026.

The appeal stays any suspension or delisting action, allowing the company's ordinary shares and warrants to continue trading on the Nasdaq Capital Market under the tickers "NRSN" and "NRSNW," respectively, pending the panel's decision.

The company said it has already regained compliance with Nasdaq's $1.00 minimum bid price requirement. The remaining deficiency is the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2). At the hearing, NeuroSense

NeuroSense schedules Nasdaq hearing for November amid listing issues

Tue, 13 Oct 2026 08:31:01 -0400

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

Tue, 13 Oct 2026 08:30:00 -0400

Shares continue to trade on Nasdaq pending the Panel's decision; minimum bid price compliance already regained

Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027

Roth/MKM Downgrades NeuroSense Therapeutics Ltd. (NRSN) to Neutral

Mon, 12 Oct 2026 16:37:39 -0400

Roth/MKM analyst Boobalan Pachaiyappan downgraded NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) from Buy to Neutral.

For an analyst ratings summary and ratings history on NeuroSense Therapeutics Ltd. click here. For more ratings news on NeuroSense Therapeutics Ltd. click here.

Shares of NeuroSense Therapeutics Ltd. closed at $3.66 yesterday.

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced it received a Staff Determination from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market.

The company was first notified on April 2, 2026, that its MVLS had fallen below $35 million for 30 consecutive trading days. Under Nasdaq rules, NeuroSense was given 180 calendar days, until September 29, 2026, to regain compliance. Having failed to meet that deadline, Nasdaq determined that the

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

NeuroSense faces Nasdaq delisting risk over market value rule

Fri, 02 Oct 2026 16:20:38 -0400

Form 6-K NeuroSense Therapeutics For: Oct 02